Oracle joins White House’s CancerX to aid the fight against cancer

Hands of a scientist, under a sterile hood, preparing the carcinoembryonic antigen (CEA) vaccinia used to try to prevent cancer | Oracle and CancerX

Oracle has been recognized as a founding member of CancerX, an inaugural project in The White House’s national Cancer Moonshot initiative.

The public-private partnership was formed to drive innovations that can help reduce deaths due to cancer. Oracle will contribute its expertise to the project, fueled by the company’s background in open cloud platforms, AI and ML, clinical research, healthcare research, care delivery and its scientific expertise from the recent acquisition of Cerner.

CancerX is co-hosted by Moffitt Cancer Center and the Digital Medicine Society (DiMe), alongside the Office for the National Coordinator for Health Information Technology and Office of the Assistant Secretary for Health.

Along with the group’s diverse innovators, Oracle will aid in defining the value of digital innovation in cancer treatment, address methodological and implementation gaps and develop best practices for the equitable adoption of digital health technologies at scale in oncology. The aim is to achieve The White House’s Cancer Moonshot goal of reducing the death rate from cancer by at least 50 percent over the next 25 years and improving the experience of people and their families living with and surviving cancer.

Seema Verma, senior vice president and general manager, Oracle Life Sciences, said: “The healthcare market continues to be highly fragmented which hinders both patient care and the quest for a cure.

“We are proud to bring our expertise in healthcare, clinical research and enterprise cloud technology to deliver more innovative and effective treatments to those fighting cancer.”

Smit Patel, associate program director, Digital Medicine Society, said: “Multi-stakeholder collaboration is critical to harness the potential of digital innovation in the fight against cancer and we’re honored to partner with Oracle to achieve the ambitious goals of CancerX.

“Through this impressive collaboration, we will establish best practices, build capacity and demonstrate the impact of innovation on the life of every person on a cancer journey.”